Docetaxel, doxorubicin and cyclophospharmide as neoadjuvant chemotherapy with primary prophylactic stem cell growth factor support in locally advanced breast cancer (T3 – T4 , No – 3, Mo)
Research in Oncology · 2006
DOI: 10.21608/resoncol.2006.354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Oncology, 2006. Verfasst von Ehab Elnakory und 2 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Elnakory, E., Abdulrazek, S., & Fawzy, A. (2006). Docetaxel, doxorubicin and cyclophospharmide as neoadjuvant chemotherapy with primary prophylactic stem cell growth factor support in locally advanced breast cancer (T3 – T4 , No – 3, Mo). Research in Oncology. https://doi.org/10.21608/resoncol.2006.354
Vancouver
Elnakory E, Abdulrazek S, Fawzy A. Docetaxel, doxorubicin and cyclophospharmide as neoadjuvant chemotherapy with primary prophylactic stem cell growth factor support in locally advanced breast cancer (T3 – T4 , No – 3, Mo). Research in Oncology. 2006. doi:10.21608/resoncol.2006.354
BibTeX
@article{Elnakory2006,
author = {Elnakory, Ehab and Abdulrazek, Samiah and Fawzy, Ashraf},
title = {Docetaxel, doxorubicin and cyclophospharmide as neoadjuvant chemotherapy with primary prophylactic stem cell growth factor support in locally advanced breast cancer (T3 – T4 , No – 3, Mo)},
journal = {Research in Oncology},
year = {2006},
doi = {10.21608/resoncol.2006.354}
}
EUVIMED